1 – Scheme overview

This scheme is intended for clinical toxicology . Molecules not provided for in the list below are added for biologists who perform toxicological screening by separation methods .

The aim of this scheme is mainly to evaluate the performance of the methods used: sensitivity and specificity.

In light of this objective, the results are not ranked.

Longitudinal studies are carried out over several years both in terms of the popularity of the methods and their performance. On this occasion the indications and recommendations of the analyzes performed are recalled.

Participating labs can choose to be assessed for all the analytes of this scheme, or simply a subset of analytes of interest.

2 – Assessment frequency

Number of investigations per year: 4
Number of control samples per investigation: 1
Number of samples per year : 4

3 – List of analytes assessed

Twelve medicinal product/drug of abuse families or molecules are systematically assessed:

• Amphetamines
• Tricyclic antidepressants
• Barbiturates
• Benzodiazepines
• Buprenorphine
• Cannabis
• Cocaine
• Ecstasy
• EDDP
• Methadone
• Methamphetamine
• Opiates

As well as other potentially toxic molecules detected using separation methods

qualitative and / or quantitative serum toxicology assays.

4 – Description of the control samples

Lyophilized human control urines (samples to be resuspended in 5 mL of distilled water).

5 – Clinical setting

A choice of clinical settings are provided with each investigation to help you identify medicinal molecules and/or drugs of abuse.